This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

New pay-for-delay deals ripe for investigation, former US FTC officials say

By Chris May ( June 30, 2025, 22:03 GMT | Insight) -- Branded drug manufacturers and their generic drug competitors have developed increasingly sophisticated ways to keep prices high through anticompetitive agreements, and the US Federal Trade Commission should open investigations into practices that were not an enforcement priority under the Biden administration, a recently retired agency veteran said today.Branded drug manufacturers and their generic drug competitors have developed increasingly sophisticated ways to keep prices high through anticompetitive agreements, and the US Federal Trade Commission should open investigations into practices that weren't an enforcement priority under the Biden administration, a recently retired agency veteran said today....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login